Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADACEL Booster in Japanese Adolescents
NCT01689324Phase 2
Key facts
- Status
- Completed
- Start
- Sep 2012
- Primary completion
- Nov 2012
- Countries
- 1
- Sponsor
- Sanofi
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Conditions
- pertussisTetanusdiphtheria
01
Overview
Phase 2, open-label trial of tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine in pertussis, Tetanus and diphtheria, sponsored by Sanofi. Primary endpoint: Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Following Vaccination With ADACEL at 28 days. Started Sep 2012; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Endpoints
Primary
Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Following Vaccination With ADACEL
Beyond the preview
Go deeper on NCT01689324.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01689324.